Bioclate (armour), recombinate, Helixate nexgen(octocog alfa)
Advate, Kovaltry (octocog alfa) is a protein pharmaceutical. Octocog alfa was first approved as Kogenate bayer on 2000-08-04. It has been approved in Europe to treat hemophilia a.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Bioclate (armour), recombinate, Novoeight, Nuwiq (discontinued: Helixate fs, kogenate, kogenate fs, Refacto)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Antihemophilic factor (recombinant)
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Novoeight | Antihemophilic Factor (Recombinant) | Novo Nordisk | A-125466 RX | 2013-10-15 | 6 products |
| Nuwiq | Antihemophilic Factor (Recombinant) | Octapharma | A-125555 RX | 2015-09-04 | 8 products |
| Bioclate (Armour), Recombinate | Antihemophilic Factor (Recombinant) | Takeda | A-103375 RX | 1992-12-10 | 5 products |
Show 2 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| altuviiio | Biologic Licensing Application | 2025-03-11 |
| recombinate | Export only | 2010-05-26 |
| xyntha | Biologic Licensing Application | 2011-01-13 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
403 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemophilia a | D006467 | EFO_0007267 | D66 | 8 | 3 | 8 | 7 | 27 | 51 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | 1 | 1 | 2 | 4 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | — | — | 1 | 1 | 2 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | — | — | 1 | — | 2 | 3 |
| Hemostatic disorders | D020141 | — | — | — | — | 1 | — | 2 | 3 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Octocog alfa |
| INN | octocog alfa |
| Description | Factor VIII is a medication used to treat and prevent bleeding in people with hemophilia A and other causes of low factor VIII. Certain preparations may also be used in those with von Willebrand's disease. It is given by slow injection into a vein.
|
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2108455 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | P89DR4NY54 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Advate – Takeda
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,010 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
11,814 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use